Korkmaz, 694 patient HCQ prophylaxis study: 82% lower mortality [p=0.19] and 94% fewer cases [p<0.0001] https://c19p.org/korkmaz
copied to clipboard
The effect of Hydroxychloroquine use due to rheumatic disease on the risk of Covid-19 infection and its course
et al., Authorea, doi:10.22541/au.162257516.68665404/v1 (Preprint)
Retrospective 683 patients in a rheumatology department, 384 chronic HCQ users and 299 control patients, showing no mortality for HCQ users vs. 2 deaths in the control group, and significantly fewer cases for HCQ users.
|
risk of death, 82.1% lower, RR 0.18, p = 0.19, treatment 0 of 385 (0.0%), control 2 of 299 (0.7%), NNT 150, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of case, 93.7% lower, RR 0.06, p < 0.001, treatment 2 of 395 (0.5%), control 24 of 299 (8.0%), NNT 13.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Korkmaz et al., 6/1/2021, retrospective, Turkey, Europe, preprint, 4 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.